Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.

European journal of clinical pharmacology - 1 Jul 2011

Bergmann Troels K, Gréen Henrik, Brasch-Andersen Charlotte, Mirza Mansoor R, Herrstedt Jørn, Hølund Berit, du Bois Andreas, Damkier Per, Vach Werner, Brosen Kim, Peterson Curt

Abstract excerpt

PURPOSE: Paclitaxel has a broad spectrum of anti-tumor activity and is useful in the treatment of ovarian, breast, and lung cancer. Paclitaxel is metabolized in the liver by CYP2C8 and CYP3A4 and transported by P-glycoprotein. The dose-limiting toxicities are neuropathy and neutropenia, but the interindividual variability in toxicity and also survival is large. The main purpose of this study was to investigate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Cytochrome P-450 CYP2C8

Share to Paclitaxel

Share to Pharmacogenetics

Share to Proportional Hazards Models

Source

Identifiers

PMID: 21327421
DOI: 10.1007/s00228-011-1007-6

Genes

ABCB1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.PMID 21327421Read ↗

Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Semantic proximity Read ↗

ABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer Patients.Semantic proximity Read ↗

Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.Semantic proximity Read ↗

GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.Semantic proximity Read ↗

ABCB1 and ERCC1 gene polymorphisms are associated with nephro- and hepatotoxicity to carboplatin/paclitaxel-based chemotherapy in patients with gynecologic cancers.Semantic proximity Read ↗

Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.Semantic proximity Read ↗

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Semantic proximity Read ↗

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.Semantic proximity Read ↗

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.Semantic proximity Read ↗

Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.Semantic proximity Read ↗

Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients.Semantic proximity Read ↗

Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.